AURORA, ON, Dec. 22 /CNW/ - Helix BioPharma Corp. (Helix; TSX, FSE:
"HBP") today announced that it has signed an agreement with Edmonton,
Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process
for L-DOS47.
"The signing of this agreement with QSV is a major step in the L-DOS47
program," said Dr. Donald Segal, President and CEO of Helix. "We believe QSV's
high caliber personnel and facilities for biopharmaceutical manufacturing will
accelerate the cGMP production of L-DOS47 for our upcoming preclinical and
human clinical studies."
